NewEdge Advisors LLC Purchases 27,163 Shares of Haleon plc (NYSE:HLN)

NewEdge Advisors LLC increased its stake in shares of Haleon plc (NYSE:HLN) by 80.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 60,949 shares of the company’s stock after purchasing an additional 27,163 shares during the period. NewEdge Advisors LLC’s holdings in Haleon were worth $581,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HLN. Wellington Management Group LLP boosted its position in shares of Haleon by 67.5% during the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after acquiring an additional 6,175,835 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Haleon during the fourth quarter worth $42,193,000. FMR LLC boosted its position in shares of Haleon by 3.7% during the fourth quarter. FMR LLC now owns 108,827,814 shares of the company’s stock worth $1,038,217,000 after acquiring an additional 3,909,545 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Haleon during the fourth quarter worth $39,628,000. Finally, JPMorgan Chase & Co. raised its stake in Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of HLN stock opened at $10.19 on Monday. The business’s fifty day simple moving average is $10.14 and its 200-day simple moving average is $9.80. The company has a market cap of $45.99 billion, a PE ratio of 29.97, a PEG ratio of 2.82 and a beta of 0.24. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $8.12 and a 12-month high of $10.80.

Haleon (NYSE:HLN) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Analysts expect that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a $0.1166 dividend. This represents a dividend yield of 1.6%. This is an increase from Haleon’s previous — dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. Haleon’s dividend payout ratio is presently 58.97%.

Analysts Set New Price Targets

HLN has been the subject of several analyst reports. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. HSBC reissued a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Hsbc Global Res downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Six equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Haleon has a consensus rating of “Hold” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.